Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Targeting Bcl-2 Proteins in Myeloma

Martine Amiot, PhD

Blood (2019) 134 (Supplement_1): SCI-11.

https://doi.org/10.1182/blood-2019-121103

Published: 2019

Journal Articles

Inhibition of ATR Overcomes Chemotherapy Resistance in p53 Deficient Myeloma Cells

Louise Bouard, MDin training, Benoit Tessoulin, MD PhD, Géraldine Descamps, PhD, Cyrille Touzeau, MD PhD, Philippe Moreau, MD, Martine Amiot, PhD, Catherine Pellat-Deceunynck, PhD

Blood (2019) 134 (Supplement_1): 3109.

https://doi.org/10.1182/blood-2019-122547

Published: 2019

Journal Articles

Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment

Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Jessie Bourcier, MD, Antoine Bonnet, MD, Géraldine Descamps, PhD, Carolane Seiller, Cyrille Touzeau, MD PhD, Philippe Moreau, Catherine Pellat-Deceunynck, PhD, Martine Amiot, PhD

Blood (2018) 132 (Supplement 1): 953.

https://doi.org/10.1182/blood-2018-99-109987

Published: 2018

Journal Articles

CSF1R and BTK Inhibitions As Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages

Antonin Papin, Benoit Tessoulin, MD, Céline Bellanger, Anne Moreau, MD, Yannick LE Bris, MDPharmD, Herve Maisonneuve, MD, Philippe Moreau, Cyrille Touzeau, MD PhD, Martine Amiot, PhD, Catherine Pellat-Deceunynck, PhD, Steven Le Gouill, MD PhD, David Chiron, PhD

Blood (2018) 132 (Supplement 1): 2855.

https://doi.org/10.1182/blood-2018-99-114504

Published: 2018

Journal Articles

Human Myeloma Cell Lines Mutation Landscape: Toward a Rationale Use of Cell Lines to Assess Drug Efficacy Prediction in Myeloma

Benoit Tessoulin, MD, Agnes Moreau-Aubry, PhD, Alban Gaignard, PhD, Martine Amiot, PhD, Catherine Pellat-Deceunynck, PhD

Blood (2017) 130 (Supplement 1): 1770.

https://doi.org/10.1182/blood.V130.Suppl_1.1770.1770

Published: 2017

Journal Articles

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Antoine Bonnet, MD, Jessie Bourcier, MD, Patricia Gomez-Bougie, PhD, Sophie Maïga, Benoit Tessoulin, MD, Philippe Moreau, MDPhD, Steven Le Gouill, MDPhD, Catherine Pellat-Deceunynck, PhD, Cyrille Touzeau, MD PhD, Martine Amiot, PhD

Blood (2017) 130 (Supplement 1): 4383.

https://doi.org/10.1182/blood.V130.Suppl_1.4383.4383

Published: 2017

Journal Articles

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Blood (2015) 126 (23): 4219.

https://doi.org/10.1182/blood.V126.23.4219.4219

Published: 2015

Journal Articles

Hypoxia-Inducible Factor (HIF)-1alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo

Paola Storti, PhD, Valentina Marchica, Denise Toscani, PhD, Irma Airoldi, PhD, Sophie Maiga, PhD, Marina Bolzoni, PhD, Nicoletta Campanini, Eugenia Martella, MD, Cristina Mancini, MD, Valentina Ferri, Gaetano Donofrio, PhD, Martine Amiot, PhD, Franco Aversa, MD, Nicola Giuliani, MD PhD

Blood (2015) 126 (23): 3012.

https://doi.org/10.1182/blood.V126.23.3012.3012

Published: 2015

Journal Articles

Biomarker and Ex Vivo Sensitivity Analysis of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Jeremy Ross, PhD, Martine Amiot, PhD, Brenda Chyla, PhD, Lisa Roberts-Rapp, Rasna Goswami, Sun Yan, Xin Huang, Anahita Bhathena, Sari Heitner Enschede, MD, Paulo Maciag, MD, Rod A. Humerickhouse, MD PhD, Evelyn McKeegan

Blood (2015) 126 (23): 2975.

https://doi.org/10.1182/blood.V126.23.2975.2975

Published: 2015

Journal Articles

BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics

Cyrille Touzeau, MD, Jeremy Ryan, SM, Philippe Moreau, MD, Triona Ni Chonghaile, PhD, Steven Le Gouill, Paul G. Richardson, Kenneth C. Anderson, Martine Amiot, PhD, Anthony G. Letai, MD PhD

Blood (2014) 124 (21): 417.

https://doi.org/10.1182/blood.V124.21.417.417

Published: 2014

Journal Articles

Mantle-Cell Lymphoma (MCL) Cells Are Highly Sensitive To ABT-199 But Their Sensitivity May Be Altered By The Microenvironment Via The Up-Regulation Of Bcl-Xl and Bcl2A1

Cyrille Touzeau, MD, Carole Brosseau, PhD, Christelle Dousset, Catherine Pellat-Deceunynck, PhD, Steven Le Gouill, MD, PhD, Martine Amiot, PhD

Blood (2013) 122 (21): 4285.

https://doi.org/10.1182/blood.V122.21.4285.4285

Published: 2013

Journal Articles

Combination Of 2-Deoxy-D-Glucose With ABT-199 Efficiently Kills All Molecular Subgroups Of Myeloma Cells

Maxime Halliez, Sophie Maïga, Cyrille Touzeau, MD, Patricia Gomez-Bougie, PhD, Steven Le Gouill, MD, PhD, Marie-Christine Bene, PharmSciD, PhD, Philippe Moreau, MD, Catherine Pellat-Deceunynck, PhD, Martine Amiot, PhD

Blood (2013) 122 (21): 1921.

https://doi.org/10.1182/blood.V122.21.1921.1921

Published: 2013

Journal Articles

Vitamin D3 and Lenalidomide Synergize To Induce Apoptosis In Mantle Cell Lymphoma Via Demethylation Of BIK

Carole Brosseau, PhD, Christelle Dousset, Cyrille Touzeau, MD, Sophie Maiga, Philippe Moreau, MD, Martine Amiot, PhD, Steven Le Gouill, MD, PhD, Catherine Pellat-Deceunynck, PhD

Blood (2013) 122 (21): 1830.

https://doi.org/10.1182/blood.V122.21.1830.1830

Published: 2013

Journal Articles

Cereblon (CRBN) Splicing Could Influence Response To IMiDs : A New PCR Strategy to Easily Detect and Semi-Quantify Loss Of The IMiDs Binding Domain

Blood (2013) 122 (21): 3107.

https://doi.org/10.1182/blood.V122.21.3107.3107

Published: 2013

Journal Articles

The p53 Reactivating Drug PRIMA-1Met Induces Apoptosis Of Myeloma Cells Via ROS Production

Benoit Tessoulin, Géraldine Descamps, PhD, Catherine Godon, Marie C Bene, PharmSciD, Philippe Moreau, MD, Steven Le Gouill, MD, PhD, Martine Amiot, PhD, Catherine Pellat-Deceunynck, PhD

Blood (2013) 122 (21): 131.

https://doi.org/10.1182/blood.V122.21.131.131

Published: 2013

Journal Articles

Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo .

Marina Bolzoni, Paola Storti, PhD, Gaetano Donofrio, PhD, Irma Airoldi, PhD, Daniela Guasco, Denise Toscani, Marco Peronaci, Eugenia Martella, MD, Mirca Lazzaretti, PhD, Luca Agnelli, PhD, Ken Patrene, Cristina Mancini, MD, Martine Amiot, PhD, Antonino Neri, Simona Colla, Judith Anderson, Franco Aversa, MD, G. David Roodman, MD, PhD, Nicola Giuliani

Blood (2012) 120 (21): 2947.

https://doi.org/10.1182/blood.V120.21.2947.2947

Published: 2012

Journal Articles

The Cap-Translation Inhibitor 4EGI-1 Induces Apoptosis in Multiple Myeloma Through Noxa Induction and Synergizes with ABT-737

Géraldine Descamps, PhD, Patricia Gomez-Bougie, PhD, Didier Bouscary, MD, PhD, Philippe Moreau, MD, Régis Bataille, PhD, Catherine Pellat-Deceunynck, PhD, Martine Amiot, PhD

Blood (2011) 118 (21): 1832.

https://doi.org/10.1182/blood.V118.21.1832.1832

Published: 2011

Journal Articles

High Bcl-2/Mcl-1 Gene Expression Ratio Identifies Molecular Sub-Groups of Multiple Myeloma Patients Extremely Sensitive to ABT-737

Linda Bodet, Catherine Pellat-Deceunynck, PhD, Patricia Gomez-Bougie, PhD, Christelle Dousset, Cyrille Touzeau, Steven Le Gouill, MD, PhD, Hervé Avet-Loiseau, MD, PhD, Regis Bataille, MD, PhD, Martine Amiot, PhD

Blood (2010) 116 (21): 4061.

https://doi.org/10.1182/blood.V116.21.4061.4061

Published: 2010

Journal Articles

Rational for a Combination of Bortezomib and Doxorubicin in the Treatment of Multiple Myeloma: A Pivotal Role for Mcl-1.

Steven Le Gouill, MD, PhD, Klaus Podar, MD PhD, Jing Zhang, Teru Hideshima, MD PhD, Martine Amiot, PhD, Chauhan Dharminder, PhD, Jean-Luc Harousseau, MD, Kenneth Anderson, MD

Blood (2007) 110 (11): 1501.

https://doi.org/10.1182/blood.V110.11.1501.1501

Published: 2007

Journal Articles

The Pan-Bcl-2 Inhibitor GX15-O70 Induces Apoptosis in Human Myeloma Cells by Noxa Induction and Strongly Enhances Melphalan, Bortezomib or TRAIL-R1 Antibody Apoptotic Effect.

Patricia Gomez-Bougie, MD, PhD, Sophie Maïga, BSc, Catherine Pellat-Deceunynck, PhD, Sandrine Jouan, MSc, Regis Bataille, MD PhD, Martine Amiot, PhD

Blood (2006) 108 (11): 3476.

https://doi.org/10.1182/blood.V108.11.3476.3476

Published: 2006

NARROW

Targeting Bcl-2 Proteins in Myeloma

Inhibition of ATR Overcomes Chemotherapy Resistance in p53 Deficient Myeloma Cells

Respective Place of Venetoclax and MCL1 BH3 Mimetics in Multiple Myeloma Treatment

CSF1R and BTK Inhibitions As Novel Strategies to Disrupt the Dialogue between Mantle Cell Lymphoma and Macrophages

Human Myeloma Cell Lines Mutation Landscape: Toward a Rationale Use of Cell Lines to Assess Drug Efficacy Prediction in Myeloma

The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse

Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results

Hypoxia-Inducible Factor (HIF)-1alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo

Biomarker and Ex Vivo Sensitivity Analysis of Venetoclax (ABT-199/GDC-0199) in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics

Mantle-Cell Lymphoma (MCL) Cells Are Highly Sensitive To ABT-199 But Their Sensitivity May Be Altered By The Microenvironment Via The Up-Regulation Of Bcl-Xl and Bcl2A1

Combination Of 2-Deoxy-D-Glucose With ABT-199 Efficiently Kills All Molecular Subgroups Of Myeloma Cells

Vitamin D3 and Lenalidomide Synergize To Induce Apoptosis In Mantle Cell Lymphoma Via Demethylation Of BIK

Cereblon (CRBN) Splicing Could Influence Response To IMiDs : A New PCR Strategy to Easily Detect and Semi-Quantify Loss Of The IMiDs Binding Domain

The p53 Reactivating Drug PRIMA-1Met Induces Apoptosis Of Myeloma Cells Via ROS Production

Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo .

The Cap-Translation Inhibitor 4EGI-1 Induces Apoptosis in Multiple Myeloma Through Noxa Induction and Synergizes with ABT-737

High Bcl-2/Mcl-1 Gene Expression Ratio Identifies Molecular Sub-Groups of Multiple Myeloma Patients Extremely Sensitive to ABT-737

Rational for a Combination of Bortezomib and Doxorubicin in the Treatment of Multiple Myeloma: A Pivotal Role for Mcl-1.

The Pan-Bcl-2 Inhibitor GX15-O70 Induces Apoptosis in Human Myeloma Cells by Noxa Induction and Strongly Enhances Melphalan, Bortezomib or TRAIL-R1 Antibody Apoptotic Effect.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only